Stem cells for poor recovery after donor transplant
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether a type of stem cell (mesenchymal stem cells) can help improve low blood cell counts after a donor stem cell transplant. It is for people whose counts are not recovering well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a donor stem cell transplant (allogeneic transplant).
- You are 18 to 60 years old.
- You are able to care for yourself most of the time (KPS score above 60).
- Your major organs (heart, liver, kidneys) are working well.
- You do not have other cancers that need treatment right now.
- You do not have a serious infection that is not under control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving extra stem cells from your original donor can help your blood cell counts recover after a transplant. It is for people whose new immune system has not fully engrafted or whose counts are dangerously low.
This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.
This study tests whether umbilical cord blood cells can help patients whose blood counts have dropped again after a stem cell transplant. It may be an option for people who have recovered initially but later develop low blood cell levels.
This trial checks how certain blood “biomarkers” change after you receive donor stem cells to rebuild your blood and immune system. The goal is to learn whether these markers can better predict your immune recovery after transplant.
This trial tests if umbilical cord stem cells can help restore low blood counts in people with leukemia, lymphoma, or myeloma who still have low blood cell levels three weeks after CAR-T therapy. It aims to improve recovery and reduce infection or bleeding risks.
This trial tests a type of stem cell transplant that removes certain immune cells (alpha-beta T cells and CD19 B cells) from the donor cells. This may help prevent graft-versus-host disease and other complications in patients with blood cancers who do not have a matched sibling donor.
Hear when a new MSC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.